Company news

Corbus Pharmaceuticals Holdings, Inc. news in 2025

Corbus Pharmaceuticals Holdings, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

December 11, 2025

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

December 10, 2025

Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

November 12, 2025

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

November 6, 2025

Corbus Pharmaceuticals Announces Pricing of Public Offering

October 31, 2025

Corbus Pharmaceuticals Announces Proposed Public Offering

October 30, 2025

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

October 18, 2025

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

October 14, 2025

Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium

October 7, 2025

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025

September 22, 2025

FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

September 16, 2025

Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

August 5, 2025

Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress

July 30, 2025

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

June 30, 2025

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

June 25, 2025

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

June 24, 2025

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 22, 2025

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 6, 2025

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

March 28, 2025

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

March 11, 2025

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

February 10, 2025

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

January 7, 2025

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Decks in 2025